444 F. App'x 401
11th Cir.2011Background
- Southeast Laborers Health and Welfare Fund sues Bayer for alleged misrepresentation or suppression of Trasylol risks in a purported nationwide class action (1999–2007).
- Allegations include civil RICO, NJCFA, and implied warranty claims arising from Bayer’s marketing and labeling of Trasylol for CABG patients.
- FDA health advisories and committee activities occurred in 2006–2007; Bayer voluntarily suspended marketing in 2007 and planned removal in 2008.
- Southeast asserts Bayer used key opinion leaders and misleading materials to justify high price and safety profile despite evidence of risks.
- District court dismissed the complaints for lack of proximate causation; on appeal, the Eleventh Circuit affirms the dismissal of NJCFA, civil RICO, and implied warranty claims.
- The decision addresses whether Southeast could establish direct causation or rely on theories like fraud-on-the-market, fraud-on-the-FDA, or direct medical-necessity causation.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| NJCFA proximate causation and loss nexus | Southeast contends direct causal link existed through non-market theory tying losses to withheld safety information. | Bayer argues no cognizable nexus; fraud-on-the-market theory inappropriate for NJCFA; losses not shown to be caused by concealment. | NJCFA claim properly dismissed; no adequate direct nexus established. |
| Fraud-on-the-market/market-based reliance in NJCFA | Southeast relies on Merck II as endorsing a causal nexus independent of fraud-on-the-market. | Fraud-on-the-market theory inappropriate outside securities context; cannot satisfy with market price alone. | Fraud-on-the-market theory foreclosed; claim dismissed. |
| Causation under Civil RICO | Southeast asserts direct chain from Bayer concealment to payment for Trasylol. | No plausible direct causation; plan decisions and medical necessity not linked to Bayer’s concealment. | RICO claim properly dismissed for lack of proximate causation. |
| Implied warranty against merchantability | Trasylol per se unmerchantable due to safety risks; drug per se unmerchantable when harmful. | Mones does not support per se unmerchantable; no physical harm shown to plan members; no proximate causation shown. | Implied warranty claim properly dismissed; no proof of merchantability defect or causation. |
| Raising new causation theories on appeal | Southeast argued omission-based causation and direct nexus; sought presumption of causation from omissions. | Argument raised too late; unsupported by record; presumption not established. | Argument waived; even if considered, theory would fail under Buckman and Merck II. |
Key Cases Cited
- Buckman Co. v. Plaintiffs’ Legal Comm., 531 U.S. 341 (U.S. 2001) (fraud-on-the-FDA claims preempted by federal law)
- Basic Inc. v. Levinson, 485 U.S. 224 (U.S. 1988) (fraud-on-the-market theory foundational; reliance presumptions)
- Merck & Co., Inc. v. Merck & Co.,, 929 A.2d 1076 (N.J. 2007) (fraud-on-the-market theory inappropriate outside securities contexts; causation limitations)
- Merck I, 894 A.2d 1136 (N.J. Super. Ct. App. Div. 2006) (class certification and causation theories in NJCFA; later reversed on denial of fraud-on-market reasoning)
- Merck II, 929 A.2d 1076 (N.J. 2007) (rejected fraud-on-the-market; reaffirmed need for traditional nexus)
- Varacallo v. Mass. Mut. Life Ins. Co., 752 A.2d 807 (N.J. Super. Ct. App. Div. 2000) (presumption of causation from omissions; limited to specific context)
- Holmes v. Sec. Investor Prot. Corp., 503 U.S. 258 (U.S. 1992) (proximate causation factors for RICO damages)
- O’Malley v. O’Neill, 887 F.2d 1557 (11th Cir. 1989) (RICO pleading standards basics)
- Am. Dental Ass’n v. Cigna Corp., 605 F.3d 1283 (11th Cir. 2010) (pleading standards for claims in the Eleventh Circuit)